Search
Protagonist Therapeutics Inc
PTGXAdd to Watchlist
103.880USD
+3.930+3.93%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
6.50BMarket Cap
LossP/E TTM
More Details of Protagonist Therapeutics Inc Company
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Protagonist Therapeutics Inc Info
Ticker SymbolPTGX
Company nameProtagonist Therapeutics Inc
IPO dateAug 11, 2016
CEOPatel (Dinesh V)
Number of employees126
Security typeOrdinary Share
Fiscal year-endAug 11
Address7707 Gateway Blvd Ste 140
CityNEWARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94560-1160
Phone15104740170
Websitehttps://www.protagonist-inc.com/
Ticker SymbolPTGX
IPO dateAug 11, 2016
CEOPatel (Dinesh V)
Company Executives of Protagonist Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
287.44K
-0.51%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
123.77K
+54.99%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
5.13K
+47.47%
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
5.13K
+47.47%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
1.93K
+54.36%
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
287.44K
-0.51%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
123.77K
+54.99%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
5.13K
+47.47%
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
5.13K
+47.47%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
1.93K
+54.36%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.94%
Farallon Capital Management, L.L.C.
9.55%
UBS Financial Services, Inc.
7.88%
RTW Investments L.P.
7.87%
State Street Investment Management (US)
4.98%
Other
56.78%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
12.94%
Farallon Capital Management, L.L.C.
9.55%
UBS Financial Services, Inc.
7.88%
RTW Investments L.P.
7.87%
State Street Investment Management (US)
4.98%
Other
56.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
41.53%
Investment Advisor
35.89%
Hedge Fund
19.80%
Venture Capital
3.81%
Research Firm
3.71%
Private Equity
2.23%
Pension Fund
1.88%
Individual Investor
0.72%
Bank and Trust
0.53%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
642
76.23M
118.60%
-3.23M
2025Q4
592
74.88M
119.78%
-4.87M
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.32M
13.04%
+299.82K
+3.74%
Dec 31, 2025
Farallon Capital Management, L.L.C.
6.14M
9.63%
-52.00K
-0.84%
Dec 31, 2025
UBS Financial Services, Inc.
2.77M
4.33%
+872.73K
+46.12%
Dec 31, 2025
RTW Investments L.P.
5.06M
7.93%
-697.22K
-12.11%
Dec 31, 2025
State Street Investment Management (US)
3.20M
5.01%
+33.93K
+1.07%
Dec 31, 2025
Wellington Management Company, LLP
3.17M
4.97%
+1.26M
+66.18%
Dec 31, 2025
Janus Henderson Investors
2.65M
4.15%
+1.55M
+140.73%
Dec 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.84%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
1.45M
2.28%
+36.28K
+2.56%
Dec 31, 2025
Woodline Partners LP
1.41M
2.21%
-29.48K
-2.05%
Dec 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Invesco S&P SmallCap Health Care ETF
2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
ALPS Medical Breakthroughs ETF
1.99%
ETC 6 Meridian Small Cap Equity ETF
1.56%
State Street SPDR S&P Biotech ETF
1.44%
Cambria Value and Momentum ETF
1.16%
Invesco S&P SmallCap Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.88%
View more
Invesco S&P SmallCap Health Care ETF
Proportion2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.33%
ALPS Medical Breakthroughs ETF
Proportion1.99%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.56%
State Street SPDR S&P Biotech ETF
Proportion1.44%
Cambria Value and Momentum ETF
Proportion1.16%
Invesco S&P SmallCap Momentum ETF
Proportion1%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.94%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.88%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
